Keyword Index for Volume 91


14-3-3 σ 1131
15d-PGJ2 633, 1074
[18F]FHPG 2079
[18F]FMISO-PET 1947
1p36 1119
3,3′-diindolylmethane 1358
4HPR 1821
5-fluorouracil 618, 1428, 1442, 1466
5-FU 1447
5-iodo-2′-deoxyuridine 366
667 COUMATE 1399
8-Cl-cAMP 186
9-cis retinoic acid 1561
α-interferon 1236
α-particle emitter 213Bi 2086
acute leukaemia 1160
acute lymphoblastic leukaemia 707
acyclovir 2079
adducts 1380
adenocarcinoma 739, 1384, 1853
adenocarcinoma of lung 771
adenocarcinoma of uterine cervix 1032
adenoid cystic carcinoma 1131
adenoma–carcinoma sequence 312
adenovirus 171, 1610
adhesion, Rho-GTPases 1800
adjuvant 1005
adjuvant chemotherapy 56
adjuvant therapy 242, 1656, 1893
adoptive immunotherapy 817
advanced 839
advanced breast cancers 861
advanced cancer 254, 1050
advanced gastric cancer 453
advanced NSCLC 1996
advanced soft tissue sarcoma 1639
age 1880
aggressive NHL 850
AKT 1420, 1735, 1808
aldehydes 111
allelic imbalance 1025
aluminium disulphonated phthalocyanine 788
American Joint Committee on Cancer stage IV 699
amputation 1012
androstenediol 1399
aneuploidy 558
angiogenesis 359, 498, 1149, 1174, 1293, 1391
angiogenesis inhibitor 1645
anthracycline 37
antibodies 1610
antibody engineering 1200
antibody processing 1500
antibody therapy 1500
antiinflammatory drug 525
antimelanoma activity 297
antioestrogen 1703
antisense 1166
antitumour activity 1624
anxiety 893
Apaf-1 1089
APC 1155, 1571
APE/ref-1 1166
APITD1 1119
apoptosis 164, 178, 195, 305, 359, 537, 580, 589, 803, 1195, 1358, 1372, 1405, 1614, 1718, 1726, 1808, 1842, 1931, 2026, 2094
ASC1 985
aspirin 525
ATM 783
attendance 1887
audit 248
autoimmunity 1508
axillary clearance 651
β-catenin 153, 1571
Bacillus Calmette-Guérin 607
base excision repair 1166
Bax 1372, 1931
B-cell lymphoma 1500
Bcl-2 164, 171
Bcr-Abl 1735
behaviour therapy 1050
belief in curability 254
benign prostatic disease 1755
benzo[a]pyrene 1380
biliary tract cancer 1769
biological 530
biomarkers 129, 725, 1190
birth weight 519, 1666
bisphosphonates 803, 1703
bladder cancer 607, 844, 1025, 2034
BMS-184476 213
body mass index 519
bone marrow 1813
bone tumour 1858
borderline tumours 1829
brain 374
brain metastases 639, 829
brain tumour 1678
BRCA 1787
BRCA1 1155, 1910
BRCA1/2 1580
BRCA2 1155, 1910
breakage–fusion–bridge cycle 327
breast 237, 954
breast cancer 69, 96, 99, 178, 233, 242, 277, 305, 413, 476, 512, 519, 618, 639, 651, 868, 873, 879, 959, 1063, 1190, 1251, 1263, 1308, 1532, 1591, 1687, 1694, 1813, 1893
breast cancer cells 1703
breast cancer family history 884
breast cancer incidence 861
breast cancer mortality 861
breast cancer screening 861
breast density 233
breast neoplasms 644, 1482, 1666, 1795
breast radiography 1795
breast radiography, quality assurance 1795
C595 monoclonal antibody 2086
CA IX 1301, 1947
cachexia 408
calcitriol 1425
camptothecin 50
cancer 56, 111, 504, 907, 1269
cancer awareness 62
cancer cachexia 1742
cancer chemoprevention 1213
cancer genetics 1829
cancer registries 1663
cancer risk 1525
cancer screening 1795
cancer services 62
cancer survival 1663
cancer symptom management 822
cancer testis antigen 141
cancer-related fatigue 822
cancer-testis antigen 1566
capecitabine 613, 834, 839, 1019, 1763, 2005
carbohydrate antigen 15-3 873
carboplatin 213, 627, 683, 1038, 1651
carcinoembryonic antigen 873
carcinoembryonic antigen-related cell adhesion molecule 6 1384
carcinogenesis 119, 195, 633
carcinoma 1515
cardiotoxicity 45
case–control study 1829
caspases 1358, 1726
cathine 1726
cathinone 1726
caveolin 959
CCI-779 1420
CD10 1342
CD20 antigen 1500
CD4+ 541
CD8+ 541
CD95 164
CDH13 1139
CDKN2A 1112
cDNA microarray 1543
cell cycle 195, 803, 1842, 2026
cell cycle arrest 1364
cell proliferation 1181, 2042
central nervous system tumour 923
central venous access port devices 1045
centrosome 327
ceramide 1821
cerebral blood volume 374
cervical cancer 84, 1032, 2056
cervical neoplasia 942
cervical screening 942
cervical smear test result 1887
cervix 1269, 1902, 2063
cervix cancer 106
cervix neoplasms 530
cervix uteri 935
cetuximab 418
CGH 775, 2063
chemoprevention 381, 1364
chemoradiation therapy 1025
chemoradiotherapy 11, 673
chemoresistance 434
chemosensitivity 666
chemotherapy 18, 476, 695, 839, 844, 1005, 1038, 1239, 1425, 1428, 1614, 1639, 1758, 1763, 1769
childhood ALL 913
childhood cancer 37, 923, 1905
childhood leukaemia 916
children 425
chromosome 16 1591
chromosome 1p 1105
chromosome 3p 1143
chromosome 9q 760
chromosome aberrations 775
chromosome instability 327
chromosome rearrangements 753
cigarette smoke 111
cigarette smoking 1280, 1525
CIN1 2056
CIN3 942
circulating tumour cells 1813
cisplatin 18, 589, 683, 1614, 2005
classic Kaposi’s sarcoma 1261
clinical trial 1645
clodronate 1703
clonality 775
clusterin 1842
c-Myc 1372
cohort study 942
colon neoplasms 1718
colorectal cancer 153, 339, 344, 381, 839, 980, 1015, 1428, 1434, 1453, 1711, 1758, 1931
colorectal carcinoma 312
colorectal liver metastases 205
combination chemotherapy 1032, 1472
communication 254
comparative study 23
complementary therapies 1482
consultant volume 459
conversion 1269
cost of illness 77
cost–benefit analysis 23
cost-effectiveness 84
Cox regression 923
COX-2 633
CpG island 707
CPT-11 482, 1205, 1434, 1442, 1447
C-reactive protein (CRP) 205, 699, 1063, 1236, 1755, 1993
cross-sectional 1575
CSF 219
CT scan 850
CTCF 1591
CTL 398, 817
cultural competence 62
cumulative incidence 1229
cure models 225
CXCR1 1970
CXCR2 1970
cyclin D 1239
cyclin D1 153
cyclin E 1239
cyclo-oxygenase 1213
cyclooxygenase 1015
cyclooxygenase-2 359
cyclophosphamide 1466
CYFRA 21-1 873
CYP1A1 1380
CYP1B1 966, 1380
cystadenocarcinoma 2048
cytochrome P450 333
cytokeratin 18 739
cytokeratin 5 739
cytokeratin-19 1813
cytokeratin-19 fragments 873
cytokine 607
cytokine receptors 1993
cytology 558
cytoskeleton 1327
cytotoxic chemotherapy 1561
cytotoxic T lymphocyte 287
cytotoxicity 1195, 2026
DARPP-32 119
database 355
DBCCR1 760
DCIS 564
DDS 1775
DEC1 954
decision-making 855
dendritic cells 1656
depression 900
deprivation 1063
desmoplastic reaction 1316
development 258
DHA-paclitaxel 1651
diagnosis 714, 1633
diet 1624
dietetics 447
differential expression 1160
differentiation 258, 1143
dihydropyrimidine dehydrogenase 1245
direct IAP-binding protein with low pI 1349
Dkk-3 707
DNA 1066
DNA adducts 333
DNA damage checkpoint 1669
DNA hypermethylation 270
DNA methylation 703, 760
DNA replication licensing 262, 714
DNA vaccine 688
DNA-PKcs 1735
docetaxel 18, 618, 1425, 1466, 1996
doublet regimens 489
Down syndrome 1866
doxorubicin 1775
doxorubicin (adriamycin) 1800
drug resistance 1166, 1405, 1800
dysplasia 1081
early discharge 651
ECarboF 1472
economic burden 77
educational attainment 923
efficacy 1434
EGFR 418, 430, 1066, 1301, 2026, 2042
EGFR family 1532
EGFR-1 470
elderly 1453
elderly NSCLC patients 489
elongation factor-1 delta 282
endocytosis 270
endometrial cancer 720, 1808
endosonography 23
enterolactone 99
epidemiology 512, 525, 644, 935, 1261, 1275, 1829
epidermal growth factor receptor 208, 795
epidermal growth factor receptor tyrosine kinase inhibitor 208
epirubicin 18, 45, 1466
EPR effect 1775
Epstein–Barr virus 572
ER gene expression 1694
ER-β 1687
ErbB2 1200, 1916
ERK 589
erlotinib 418
ET-1 434
ETAR 434
ETBR 434
etoposide 659, 1038, 1842
Ets transcription factors 1308
evaluation 935
Ewing’s sarcoma 225, 1858
experimental therapeutics 1808
expression 1515
extracellular domain 430
extracellular matrix 1327
extracellular matrix proteins 1964
family cancer history 1575
family history 96, 929
Fas 164
Fas receptor 1718
Fas-associated phosphatase-1 1718
FBP 270
feasibility 627
FHIT 2056
Fhit deficiency 1669
Fhit protein 1669
first pregnancy 512
first-line chemotherapy 1466
FISH 558
flavonoids 1364
fludarabine 695
folinic acid 453
follicular 695
follicular thyroid tumours 732
fractionated cisplatin 844
fractionated irradiation 1543
fragile histidine triad gene (FHIT) 1571
fragile sites 753
free radicals 111
full length TRAIL 171
function 1858
functional analysis 1287
galectin-3 1096
ganciclovir 2079
gangliosides 389
gastric adenocarcinoma 11
gastric cancer 1139, 1245, 1924
gastric caner 1335
gastric carcinoma 18, 1342
gastrointestinal cancer 834
GD1b synthase 389
gefitinib 208, 418, 1964, 2026
gemcitabine 482, 489, 673, 844, 1166, 1763
gemcitabine ovarian cancer 627
Geminin 262
gene amplification 725
gene expression 666, 1015, 1089, 1597
gene polymorphism 1551
gene profiling 200
gene therapy 817, 1610, 2079
gene–environment interaction 339
genetic counselling 1580
genetic pathway 312
genetic risk 1575
Gleason score 1755
glioblastoma 1195
glioma 374, 745, 1174, 1656
glioma survival 1678
glycolysis 2094
granulocytes 1316
growth 519
growth factor receptor 666
growth inhibition 580
growth pattern 1293
growth regulation 1955
GSTP1 985
guidelines 4
Guthrie cards 913
haemoglobin oxygen saturation 788
haptoglobin 129
haptoglobin-1 precursor (HAP1) 129
Hashimoto’s thyroiditis 1096
HCC 1964
HD 850
head and neck cancer 1477
head and neck neoplasms 124
head and neck squamous cell carcinoma 2005
health anxiety 893
height 519
Helicobacter pylori 929
heparin 30
hepatoblastoma 972
hepatocarcinogenesis 1955
hepatocellular carcinoma 753, 1561
HER-2 430, 795
HER2/neu 959, 1195, 1308
HER3 2034
HER4 2034
Herceptin 1190
heregulins 2034
herpes simplex virus thymidine kinase 2079
herpes virus 913
herpes zoster 1275
hierarchical cluster analysis 319
hierarchical clustering 775
HIF-1α 954
high risk 69
high-dose 5-fluorouracil 453
high-grade gliomas 425, 1038
histocompatibility antigens class II 1500
histological subtype 1143
HLA-A24 287
HLH 1990
hMLH1 1155
hMSH2 1155
HNPCC 1155, 1287
HO-1 1551
Hodgkin’s disease 572
homeodomain 258
hormonal receptor 959
hormone replacement therapy 644
hospital teams 248
hospital volume 459
household and family 907
HPV 942, 1269
HPV16 2056
human 1880
human bronchial epithelial cells 333
human gastric mucin 1342
human melanoma cell lines 297
human papillomavirus 84
human telomerase reverse transcriptase 972
hypersensitive patients 1251
hypersensitivity 213
hypoalbuminaemia 205
hypopharynx 258
hypoxia 374, 954, 1181, 1947
IκB 381
Id-1 2042
IFN-gamma 688
IGF1 1735
IGF-binding proteins 1525
IL-6 1074, 1335
IM862 1645
immune escape 1718
immune response 688
immune therapy 1880
immunohistochemistry 119, 434, 552, 1342, 1532, 1556, 1591
immunotherapy 398, 607, 688, 1200, 1656
inadequate 1887
incidence 77, 916, 1275
indicator 972
induction 1624
infections 1866
inflammatory cytokines 1993
information needs 855
information services/*standards/utilisation 1482
informative censoring 1229
inhibition of cell proliferation 2094
insulin-like growth factors 1525
integrins 1327
interaction 233
interferon 164
interferon-alpha 621
interleukin-6 1755
interleukin-8 1327
interleukin-8/CXCL8 1970
internet 1482
internet/*standards/utilisation 1482
interstitial therapy 441
interventional radiologists 1045
intestinal lesions 1571
intestinal polyps 1571
intratumoral CD8+ T cells 1711
invasion 745, 1308, 1384, 1556, 1800
iodine 544
ionising radiation 2026
IRES vector 1842
Iressa 208
irinotecan 659, 678, 1245, 1434, 1447, 1453
ischaemia reperfusion injury 788
JACC study 929
JAK 1074
Kaplan–Meier estimate 1229
Khat 1726
Ki-67 262, 2018
KIT 2048
knowledge 855
lactate dehydrogenase (LDH) 699
Laminin-5 1964
laser capture microdissection 1096
late cardiac toxicity 37
leptomeningeal metastasis 219
leucovorin 1442, 1758
leukaemia 186, 1866
leukaemia cells 1726
LightCycler 972
lignan 99
limb-sparing surgery 1012
LINE retrotransposons 985
liposomal doxorubicin 1639
liquid-based cytology 84
liver enzymes 205
liver perfusion 1610
Lokich 1447
longitudinal 907
long-term response 1873
loss of heterozygosity 760, 1105, 1143
loss to follow-up 106
lower extremity 1858
lower extremity sarcomas 1012
lung 1515
lung adenocarcinoma 1143
lung cancer 208, 537, 1149, 1280, 1970, 2018
lung carcinogenesis 1380
lymphangiogenesis 498
lymphatic metastasis 124
lymphoma 141, 695
MAG-CPT 50
MAGE 398
magnetic resonance imaging 23, 374
maintenance therapy 621
malignancy grade 644
malignant effusion 558
malignant melanoma 765
mammaglobin 1813
mammary carcinoma 1200
mammary gland 1372
mammography 413
mammography screening 242
MAPK 1405
mass screening 530, 900
maternal hypertension 1666
MCF-7 1821
MCF-7 cells 178
MCM 262
Mcm5 714
MDM2 1415
measles virus 572
medical oncology 900
MEK 589
melanoma 699, 803, 829, 1089, 1495
membrane transport 2079
menarche 519
mesoionic compounds 297
mesothelioma 9
Met expression 703
meta-analysis 2018
metabolism 1213
metabolites 333
metalloprotease inhibitor 30
metastases 1782
metastasis 359
metastatic 683
metastatic breast cancer 77, 1466
metastatic colorectal cancer 1447
metastatic lymph node 466
METH-2 1149
methotrexate 1428
methylation 707, 739, 771, 1131, 1149, 1335, 1835, 2071
methylselenol 195
MIC-A/B 1495
micelle 1775
microarrays 1112, 1160, 1614, 1924, 1931
MI-D 297
mismatch repair 1287
missing covariate data 4
mitogen-activated protein kinase 178, 795
mitomycin C 834, 839, 1624
mitomycin C resistance 1669
mitosis 537
mitoxantrone 1005
MLL cleavage and rearrangement 1990
MLPA 1155
MMP-9 1301, 1384
models 530
molecular markers 552
molecular staging 558
monitoring 873, 935
monochromatic synchrotron radiation 544
monoclonal antibody 725, 1195
mortality 242, 1902
motility 1800
mouth 1551
MSH6 1287
MTAP 1112
m-TOR 1420
MUC1 1633
MUC-1 mucin 2086
MUC2 1342
MUC4 1633
MUC6 1342
mucin 1633
mucoepidermoid carcinoma 1131
multicenter trial 45
multimedia 855
multimodality treatment 666
multiple breast carcinomas 775
multiple myeloma 1873
multiple testing 1160
multivariate analyses 1711
muscle 408
muscle wasting 1742
mutation 355, 2048
myoepithelial cells 564
natural product 1405
need for control 254
neoadjuvant chemotherapy 2012
neoplasm 1551
neoplasm seeding 9
nested case–control study 929
neuroblastoma 389, 1112, 1119, 1205, 1835
NF-κB 381, 1742
NK 1495
NK911 1775
NKG2D 1495
NKT cells 1880
nonangiogenic growth 1293
non-small-cell lung cancer 430, 771, 1293, 1993
nonsteroidal anti-inflammatory drug 153
NQO1 1624
NSAIDs 381
NSCLC 171, 482, 1301
nuclear factor I-B3 1112
nuclear sites 916
nucleus 537
nude mice 1364
nurse led 651
nutrition support 447
oesophageal cancer 714, 1139, 1543, 1556
oesophageal neoplasms 282
oesophageal squamous cell carcinoma 119
oestrogen receptor 1703, 2012
oestrogen receptor beta 1694
oestrogens 178, 644, 1399
oestrone sulphate 1399
older people 907
oligoastrocytoma 1105
oligodendroglioma 262, 1105
oral 111, 1459
oral carcinoma 760
oral chemotherapy 613
oral contraceptives, ovarian cancer 1910
oral squamous cell carcinoma 1074
oral submucous fibrosis 1551
organotypic brain slice cultures 745
osteosarcoma 1858
outpatient 844
ovarian cancer 129, 621, 725, 1614, 1829, 1916, 2042
ovarian carcinoma 470
ovarian neoplasms 2048
ovarian tumour 633
overall survival probability 1229
oxaliplatin 453, 1428, 1758, 1931
oxygenation 1181
p16INK4a 771
p21 262, 1239
P450 reductase 966
p53 178, 1025, 1131, 1415, 1614, 1931
p53 activity 1488
p53 gene mutation 1081
p53 overexpression 1081
p73 1025
paclitaxel 45, 489, 1639
paclitaxel (taxol) 1800
PAH 333
PAI-1 564
palliative 1005
palliative care 248, 900, 907, 1050
palliative radiotherapy 829
pancreatic cancer 459, 673, 1166, 1316, 1327, 1384, 1633
pancreatic cancer cell lines 2086
pancreatic tumours 2086
papillary carcinoma of the thyroid 703
papillomavirus 2063
parathyroid hormone-related protein (PTHrP) 287
PAS domain 141
pathological response 2012
pathology 23
patient survival 2034
pattern of failure 11
PAX8 732
PC3 cells 1358
PCR 913
PCR–SSCP 312
PDGFRA 2048
pegylated liposome 366
pentose cycle 2094
peptides 287, 1488
performance status 1236, 1453
perfusion 1181
peritoneal cytology 720
persistence 1269
PET scan 850
phaeochromocytoma 1835
pharmacogenetics 344, 678
pharmacokinetics 50, 1434, 1769, 1775
phase I 1459, 1651
phase I study 1032
phase I trial 1019
phase II study 1032, 1769
photodynamic therapy 441, 788
phyto-oestrogen 99
PI3K pathway 1420
pimonidazole 1947
place of death 907
platinum therapy 344
polygenic model 1580
polymeric 50
polymorphisms 344, 339, 783
population-based cohort study 923
population-based studies 1263
positron emission tomography 2079
postmenopausal 1666
PPARγ 633, 732
predictive 1239
predictive factors 1263
predictive genetic testing 1787
predictive marker 1025
prenatal origin 913
preneoplasia 1515
preoperative 434
preoperative breast biopsy 1782
preoperative radiotherapy 1019
pretreatment parameters 1873
prevalence 1575
primary vaginal and cervical cancers 319
prodrug 366
progestin 644
prognosis 119, 237, 277, 430, 466, 470, 498, 552, 720, 829, 972, 1275, 1293, 1556
prognostic factors 96, 219, 282
prognostic index 829
prognostic marker 1391
prognostic models 4
prolactin 305
proliferative factor 2018
promoter methylation 1597
promoter polymorphism 765
pro-peptide 1955
prospective study 99
prostate 195, 1842
prostate cancer 287, 541, 580, 688, 855, 1005, 1358, 1425, 1472, 1755
prostate cancer susceptibility 783
prostate neoplasm 1853
prostate-specific antigen 688, 1853
prostatic intraepithelial neoplasia 739
proteasome expression 1742
protein degradation 408
protein expression 319
protein kinase A 186
protein synthesis 408
protein–protein interaction 1415
proteomics 129
proto-oncogene 282
psychological distress 504, 884
psycho-oncology 504
psychosocial 879
psychosocial aspects 504
psychosocial functioning 855
psychosocial interventions 1050
psychosocial issues 1787
PTEN 1420, 1808
PTGS2/COX2 339
purging 186
pyridoxal 5′-phosphate 1508
pyridoxal phosphatase 1508
Q-TWiST 1893
quality assurance 248
quality assurance, health care 1482
quality of life 56, 69, 1012, 1050, 1858, 1893, 1996
quality-adjusted survival 1893
quantitative real-time PCR 282
quantitative RT–PCR 1316
quercetin 1213
quinazoline 1066
radiation 868
radiation dose enhancement 544
radiation oncology 447
radiation therapy 1678
radical prostatectomy 1853
radioimmunoconjugate 2086
radioresistance 1543
radiosensitiser 366
radiosensitivity 666
radiosentitiser 673
radiotherapy 9, 23, 544, 868, 1239, 1251
Rapamycin 1420
RAR antagonists 580
RARB2 985
real-time RT-PCR 333, 1924
reassurance 893
receptor status 644
record linkage 92
rectal cancer 1019
rectal neoplasm staging 23
rectal neoplasms therapy 23
recurrence 2063
recurrence pattern 1342
recurrent head and neck cancer 441
redox metals 111
reflectance spectroscopy 788
registry 923
relative excess risk of death 1263
relative survival 1263, 1663
remission 893
renal cancer 1236
renal cell cancer 1645
renal cell carcinoma 164, 327, 966, 1349, 1763
reporting 4
resection 459
resistance 1205
response prediction 666
restaging 850
resveratrol 178, 333, 1380
retinoic acid 389
retinoic acid receptors 580
retroviral vector 1488
review 237
ribose synthesis 2094
rice bran 1364
risk 92, 1275
risk counselling 884
risk factors 45, 233
risk management 1787
risk modifiers 1580
ROC curve 1160
RT–PCR 200, 1813
S-1 1245, 1769
S100 739
S100A2 1515
safety 1434
saliva 111
salvage chemotherapy 659
sarcoma 237
satisfaction 884
satisfaction with information 1887
scaffold protein 1488
screening 69, 84, 413, 935, 1902
SDHB 1835
second line 659, 1996
second malignancy 868
second malignant neoplasm 1905
second mitochondria-derived activator of caspases 1349
second-line chemotherapy 482, 1442
selenium 195
selenomethionine 195
seminoma 683
sensitive relapse 659
sentinel lymph-node biopsy 124
sentinel node 1782
sequential paclitaxel 627
SEREX 141
serine protease 725
serology 1269
serous 2048
serum antibody 1566
serum lipids 476
serum marker 699
sex difference 929
SF-36 879
SFRP1 985
shedding 1500
siRNA 1384
skin cancer 1604
SLIT1 2071
SLIT3 2071
small GTPases 270
small molecule 1415
small-cell lung cancer 659
smoking 512
SN-38 678
socioeconomic status 879
SOCS-1 1335
solid tumours 1459
somatic 355
South Asian 62
southern Sardinia 1261
SPARC 1924
specialisation 459
sperm protein 17 1597
SRC-1 1687
stable isotope-based dynamic metabolic profiling (SIBDMAP) 2094
stage 720
stage IV breast cancer 77
standards 248, 1477
Stat3 1074, 1335
state anxiety 1887
statistical methods 1663
steroid sulphatase 1399
steroids 525
stomach cancer 929
stool 980
stromal macrophages 498
subcutaneous fibrosis 1251
sunlight 1604
surgery 23
survival 4, 106, 237, 459, 541, 720, 1236, 1275, 1453, 1477
survival analysis 1293
survivin 537
synergy 171
systematic review 1050, 2018
systemic inflammatory response 1063, 1236
TAA 398
Tabar classification 233
tamoxifen 476, 1251, 1694
targeted therapy 795
taxanes 213, 1005, 1651
TCC 398
telomerase 972
telomere 327
temozolomide 425
TFIID 1119
TGCT 589
TGF-β 1316
Tg-mRNA 200
thalidomide 1873
therapeutic intervention 966
therapy 1633
thymidylate synthase 1245
thyroglobulin 200
thyroid cancer 1096
thyroid carcinoma 200
tissue array 537
tissue inhibitor of matrix metalloproteinase 3 (TIMP-3) 1556
tissue microarray 1089, 1532
T-lymphocytes 541
topoisomerase I inhibitor 1459
topoisomerase IIα 1038
total PSA 1755
toxicity 1453
TP53 1119, 1916
transcription factor 1566
transforming growth factor α 1955
transgenic mice 1372
transitional cell carcinoma 552
transudate 558
trastuzumab 639, 959
treatment choice 56
treatment-related leukaemia 1990
trends 1902
triazene 1066
troglitazone 1561
tumorigenesis 1372, 1566
tumour growth 1964
tumour immunity 1711
tumour M2-PK 980
tumour marker 699
tumour necrosis factor 30
tumour prestages 1955
tumour progression 1349, 1694
tumour screening 980
tumour size 277, 959
tumour suppressor gene 753, 1105, 1571
tumour vaccination 1656
tumour volume 205
tumours 237, 374, 954, 966, 1947, 2071
tyrosine kinase 1735
tyrosine kinase inhibitor 1174, 1391
Tyrphostin AG1024 1735
UFT 613, 1758
UGT1A1 678
ulcerative colitis 1081
underexpression 732
uPAR 564
urban and rural area 1261
urokinase plasminogen activator (uPA) 1308
uterine cervical cancer 466
utility 1893
UVC resistance 1669
uvea 1495
vaccine 817
vascularity 1181
VDR 765
VEGF 219, 498, 1174, 1181, 1391
VEGF-C 466
VEGFR2 1391
venous thromboembolism 92
vinorelbine 489
vitamin D 1425
waiting times 1477
website 355
weekly schedule 1996
worry 1787
WWOX gene expression 753
xenograft 1205
X-linked inhibitor of apoptosis 1349
XR11576 1459
XRCC1 1604
ZD1839 208
ZD6474 1174
zinc-finger protein 1566
